Jason Gerberry
Stock Analyst at B of A Securities
(3.56)
# 890
Out of 4,670 analysts
149
Total ratings
55.24%
Success rate
3.29%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLUE bluebird bio | Downgrades: Neutral | $3 → $0.5 | $0.35 | +42.82% | 8 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Buy | $84 → $100 | $90.44 | +10.57% | 4 | Nov 6, 2024 | |
| EXEL Exelixis | Maintains: Buy | $30 → $32 | $35.61 | -10.14% | 1 | Oct 15, 2024 | |
| BHVN Biohaven | Maintains: Buy | $52 → $62 | $45.59 | +35.99% | 1 | Sep 24, 2024 | |
| RLAY Relay Therapeutics | Maintains: Buy | $20 → $24 | $4.75 | +405.26% | 1 | Sep 10, 2024 | |
| PROK ProKidney | Maintains: Neutral | $4 → $3 | $1.69 | +77.51% | 3 | Sep 4, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $101 → $140 | $88.54 | +58.12% | 3 | Sep 4, 2024 | |
| AXSM Axsome Therapeutics | Upgrades: Buy | $95 → $106 | $98.68 | +7.42% | 4 | Aug 6, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $67 → $68 | $34.01 | +99.94% | 5 | Jul 23, 2024 | |
| OCS Oculis Holding AG | Maintains: Buy | $21 → $20 | $14.76 | +35.50% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $17.12 | +22.66% | 12 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $91 | $85.69 | +6.20% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $27.13 | +14.26% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $0.19 | +5,720.11% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $21.48 | +7.08% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $28.78 | +0.76% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $18.54 | +99.57% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $41.15 | +36.09% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $34.07 | -11.95% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $51 | $26.87 | +89.80% | 3 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $63 | $45.46 | +38.58% | 1 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $13.37 | -32.69% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $126.67 | +71.31% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $4 → $2 | $0.40 | +405.82% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $748.01 | -33.16% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $6 → $4 | $0.31 | +1,211.05% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $2.21 | +307.24% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $15.28 | +63.61% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.74 | +187.36% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $7.97 | +238.77% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.09 | +1,734.86% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $10 | $0.99 | +905.53% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $176.95 | -46.31% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $58.87 | +1.92% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $25.65 | +44.25% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $99.18 | -9.26% | 11 | Oct 17, 2019 |
bluebird bio
Nov 15, 2024
Downgrades: Neutral
Price Target: $3 → $0.5
Current: $0.35
Upside: +42.82%
Arcellx
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $90.44
Upside: +10.57%
Exelixis
Oct 15, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $35.61
Upside: -10.14%
Biohaven
Sep 24, 2024
Maintains: Buy
Price Target: $52 → $62
Current: $45.59
Upside: +35.99%
Relay Therapeutics
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $4.75
Upside: +405.26%
ProKidney
Sep 4, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $1.69
Upside: +77.51%
Vaxcyte
Sep 4, 2024
Maintains: Buy
Price Target: $101 → $140
Current: $88.54
Upside: +58.12%
Axsome Therapeutics
Aug 6, 2024
Upgrades: Buy
Price Target: $95 → $106
Current: $98.68
Upside: +7.42%
Ionis Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $67 → $68
Current: $34.01
Upside: +99.94%
Oculis Holding AG
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $14.76
Upside: +35.50%
May 30, 2024
Maintains: Buy
Price Target: $18 → $21
Current: $17.12
Upside: +22.66%
Apr 17, 2024
Maintains: Buy
Price Target: $82 → $91
Current: $85.69
Upside: +6.20%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $27.13
Upside: +14.26%
Mar 25, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $0.19
Upside: +5,720.11%
Mar 7, 2024
Initiates: Buy
Price Target: $23
Current: $21.48
Upside: +7.08%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $28.78
Upside: +0.76%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $18.54
Upside: +99.57%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $41.15
Upside: +36.09%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $34.07
Upside: -11.95%
Dec 21, 2023
Maintains: Buy
Price Target: $49 → $51
Current: $26.87
Upside: +89.80%
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $45.46
Upside: +38.58%
Oct 23, 2023
Downgrades: Underperform
Price Target: $9
Current: $13.37
Upside: -32.69%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $126.67
Upside: +71.31%
Aug 8, 2023
Downgrades: Underperform
Price Target: $4 → $2
Current: $0.40
Upside: +405.82%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $748.01
Upside: -33.16%
May 16, 2023
Maintains: Underperform
Price Target: $6 → $4
Current: $0.31
Upside: +1,211.05%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $2.21
Upside: +307.24%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $15.28
Upside: +63.61%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.74
Upside: +187.36%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $7.97
Upside: +238.77%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.09
Upside: +1,734.86%
Jul 15, 2020
Downgrades: Neutral
Price Target: $17 → $10
Current: $0.99
Upside: +905.53%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $176.95
Upside: -46.31%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $58.87
Upside: +1.92%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $25.65
Upside: +44.25%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $99.18
Upside: -9.26%